Intratumoral susceptibility signals on susceptibility-weighted imaging for glioma grading and molecular profiling: a systematic review and meta-analysis
In brief
Signal scoring distinguished higher-grade gliomas with 85% sensitivity and 93% specificity
In a meta-analysis of 19 studies and 1,383 patients, a susceptibility-weighted MRI signal threshold of at least 2 distinguished grade III-IV from grade II gliomas with 85% sensitivity and 93% specificity. Lower thresholds caught more higher-grade tumors but produced more false positives, while higher thresholds improved specificity at the cost of sensitivity. Molecular links, including to isocitrate dehydrogenase wild-type tumors, remain exploratory.
- Journal
- AJNR. American journal of neuroradiology (Q1)
- Published
- 9 October 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- Arian Allaei, Humberto Abraham Cortés Magdaleno, Elisabeth Amadeo, Karabo Kago Marole, Guilherme Alexandre Quint, Samir Shinnawi
- PMID
- 42855273
- DOI
- 10.3174/ajnr.A9672
Why clinicians should know about it
- Picked for Radiology, Radiation Oncology, Nuclear Medicine, Medical Physics and Imaging (paper of the day, 11 October 2026): Intratumoral susceptibility signals as MRI biomarker for glioma grading
Abstract
BACKGROUND: Intratumoral susceptibility signals on susceptibility-weighted imaging have emerged as a potential biomarker for glioma grading and molecular characterization. PURPOSE: To evaluate the diagnostic performance of intratumoral susceptibility signals for glioma grading using harmonized World Health Organization grade contrasts. DATA SOURCES: PubMed, Embase, and Cochrane were searched from inception through December 18, 2025. STUDY SELECTION: Studies reporting preoperative semiquantitative assessment of intratumoral susceptibility signals in histologically confirmed gliomas were included; grading reference standards ranged from histology-based to integrated 2021 World Health Organization histomolecular diagnosis. DATA ANALYSIS: The primary analysis compared World Health Organization grades III-IV with grade II. Alternative contrasts were analyzed separately. Threshold-specific sensitivity and specificity were pooled when at least 3 comparable studies were available. Observed-only and leave-one-out analyses assessed robustness. DATA SYNTHESIS: Nineteen studies including 1383 patients were included; 10 contributed to quantitative grading analyses. For World Health Organization grade III-IV versus II, pooled sensitivity and specificity were 0.96 (95% CI, 0.86-0.99) and 0.48 (0.22-0.75) at an intratumoral susceptibility signal threshold ≥1, 0.85 (0.74-0.91) and 0.93 (0.84-0.97) at threshold ≥2, and 0.72 (0.59-0.82) and 0.97 (0.93-0.99) at threshold ≥3. Molecular findings were heterogeneous and summarized descriptively, with higher intratumoral susceptibility signal burden most consistently associated with isocitrate dehydrogenase wild-type status. LIMITATIONS: Studies were predominantly retrospective and single-center, with heterogeneous intratumoral susceptibility signal scoring, imaging protocols, and World Health Organization reference standards. Some contingency tables required reconstruction. CONCLUSIONS: Intratumoral susceptibility signals showed threshold-dependent performance for distinguishing World Health Organization grade III-IV from grade II gliomas. Among the prespecified ordinal thresholds, a threshold ≥2 provided the most balanced sensitivity-specificity profile. Molecular evidence remains exploratory.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.